April 28, 2020 - Events
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an IgE antibody as a treatment for advanced cancer London, 27 April 2020 – Epsilogen (formerly IGEM...
April 20, 2020 - Press Releases
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer London, 20 April 2020 – Epsilogen (formerly IGEM Therapeutics), a global leader in the...
April 20, 2020 - Press Releases
MOv18 IgE is currently in phase 1 clinical trial in cancer patients with advanced solid tumours Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer Investors commit to a further £3 million Series A2 financing of...
